278
M. Chen et al.
advance regulatory science and personalized medicine. The most visible projects from his group
are (1) leading the Microarray Quality Control (MAQC) consortium to develop standard analysis
protocols and quality control metrics for emerging technologies to support regulatory science and
precision medicine; (2) development of liver toxicity knowledge base (LTKB) for drug safety; (3)
in silico drug repositioning for the enhanced treatment of rare diseases; and (4) development of the
FDA bioinformatics system, ArrayTrackTM suite, to support FDA review and research on pharmacogenomics. In addition, his group also specializes in molecular modeling and QSARs with
specific interest in estrogen, androgen, and endocrine disruptor. Dr. Tong has published more than
230 papers and book chapters.
M. Chen et al.
advance regulatory science and personalized medicine. The most visible projects from his group
are (1) leading the Microarray Quality Control (MAQC) consortium to develop standard analysis
protocols and quality control metrics for emerging technologies to support regulatory science and
precision medicine; (2) development of liver toxicity knowledge base (LTKB) for drug safety; (3)
in silico drug repositioning for the enhanced treatment of rare diseases; and (4) development of the
FDA bioinformatics system, ArrayTrackTM suite, to support FDA review and research on pharmacogenomics. In addition, his group also specializes in molecular modeling and QSARs with
specific interest in estrogen, androgen, and endocrine disruptor. Dr. Tong has published more than
230 papers and book chapters.